Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Methods of treatment using single doses of oritavancin|
|Abstract:||Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.|
|Inventor(s):||Lehoux; Dario (Terrebonne, CA), Parr; Thomas R. (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA), Etienne; Pierre (Montreal, CA)|
|Assignee:||The Medicines Company (Parsippany, NJ)|
1. A method of treating a complicated skin and skin structure infection (cSSSI) in a subject, comprising administering a single dose of a therapeutically effective amount of a
pharmaceutical composition comprising oritavancin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent, over a course of therapy to a subject having cSSSI, wherein the single dose comprises at least 1200 mg
oritavancin, or a pharmaceutically acceptable salt thereof, thereby treating cSSSI in the subject.
2. The method of claim 1, wherein the single dose comprises between 1200 mg to 1800 mg oritavancin, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1, wherein said administering is via intravenous administration or oral administration.
4. The method of claim 1, wherein the bacteria causing cSSSI a is one or more bacteria selected from the group consisting of a gram-positive bacteria, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate Staphylococcus aureus, vancomycin hetero-intermediate Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus, Streptococcus dysgalactiae, Streptococcus dysgalactiae subsp. equisimilis, Enterococcus faecalis, vancomycin-resistant Enterococcus faecalis, Enterococcus faecium, and vancomycin-resistant Enterococcus faecium.